HealthCap

Tribune Therapeutics is a preclinical biopharmaceutical company dedicated to advancing novel therapies for fibrotic diseases. They focus on developing innovative medicines targeting the CCN protein family, which plays a crucial role in fibrosis development. Their pipeline aims to address a broad spectrum of fibrotic conditions, offering potential new treatment options for patients.

HelloBetter is a pioneering company in the field of digital therapeutics for mental health, founded in 2015 as a university spin-off by renowned research psychologists. Headquartered in Hamburg, Germany, with an additional office in Berlin, HelloBetter offers a range of online psychological training programs aimed at managing conditions such as stress, depression, anxiety, panic disorders, and sleep disturbances. The company's innovative approach has led to the approval of six of its online therapy programs as prescription digital therapeutics under the German DiGA framework, allowing them to be accessed at no cost by over 73 million people in Germany. With a total of ten digital therapeutics evaluated in numerous randomized controlled trials, HelloBetter is committed to making evidence-based mental health care accessible worldwide. The company is actively expanding its reach beyond the DACH region, supported by a recent funding round.

SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.

Kivu Biosciences, based in San Francisco, is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company aims to deliver superior therapeutics and rapidly advance transformative assets, operating discreetly while focusing on its innovative pipeline.

ADCendo ApS is a biotech company focused on the development of innovative anti-cancer therapies, specifically through the creation of antibody-drug conjugates (ADCs). These conjugates are designed to target receptors that are overexpressed in various forms of cancer, addressing significant unmet medical needs in the treatment landscape. ADCendo's approach aims to enhance targeted therapy for patients suffering from conditions such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, among others. By developing new medicines that effectively target carcinomas—including breast, colon, pancreatic, prostate, ovarian, and renal cancers—ADCendo seeks to improve treatment outcomes for cancer patients.

SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

Rampart Bioscience is a biotechnology company focused on developing gene medicines that aim to deliver long-lasting treatments for various diseases. The company has created proprietary development and delivery platforms that generate optimized therapeutics in a revocable, non-viral format. By integrating expertise from multiple scientific disciplines, including gene delivery, protein sciences, and clinical translation, Rampart Bioscience works to assist patients with genetically driven diseases. Their innovative approach seeks to enhance the effectiveness and safety of gene therapies, ultimately improving patient outcomes.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

HelloBetter is a pioneering company in the field of digital therapeutics for mental health, founded in 2015 as a university spin-off by renowned research psychologists. Headquartered in Hamburg, Germany, with an additional office in Berlin, HelloBetter offers a range of online psychological training programs aimed at managing conditions such as stress, depression, anxiety, panic disorders, and sleep disturbances. The company's innovative approach has led to the approval of six of its online therapy programs as prescription digital therapeutics under the German DiGA framework, allowing them to be accessed at no cost by over 73 million people in Germany. With a total of ten digital therapeutics evaluated in numerous randomized controlled trials, HelloBetter is committed to making evidence-based mental health care accessible worldwide. The company is actively expanding its reach beyond the DACH region, supported by a recent funding round.

ADCendo ApS is a biotech company focused on the development of innovative anti-cancer therapies, specifically through the creation of antibody-drug conjugates (ADCs). These conjugates are designed to target receptors that are overexpressed in various forms of cancer, addressing significant unmet medical needs in the treatment landscape. ADCendo's approach aims to enhance targeted therapy for patients suffering from conditions such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, among others. By developing new medicines that effectively target carcinomas—including breast, colon, pancreatic, prostate, ovarian, and renal cancers—ADCendo seeks to improve treatment outcomes for cancer patients.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Spruce Biosciences, Inc. is a biopharmaceutical company based in Daly City, California, specializing in the development and commercialization of innovative therapies for rare endocrine disorders. Founded in 2014, the company is primarily focused on its lead product candidate, tildacerfont, which is undergoing clinical trials for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH). Tildacerfont is being developed as a non-steroidal therapy aimed at improving disease management and reducing reliance on steroids for affected patients. Additionally, the company is exploring the use of tildacerfont for females with polycystic ovary syndrome. With a commitment to addressing the unmet medical needs of patients with rare endocrine conditions, Spruce Biosciences aims to enhance the quality of life for those who have been historically underserved by existing treatment options. The company also has a partnership with Eli Lilly and Company to explore further pharmaceutical applications of its compounds.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company that focuses on the detection and targeted treatment of aggressive cancers, particularly neuroendocrine tumors and other challenging malignancies. The company's lead product, 177Lu-satoreotide tetraxetan (Satoreotide), acts as an antagonist of the somatostatin type 2 receptor (SSTR2), which is commonly overexpressed in many neuroendocrine tumors. Ariceum is developing Satoreotide as a theranostic pair, which allows for both the diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, certain aggressive tumors, and childhood cancers. This approach aims to provide treatment options for conditions that currently have limited therapies and poor prognoses, enabling healthcare professionals to deliver more effective treatments with reduced side effects.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

HelloBetter is a pioneering company in the field of digital therapeutics for mental health, founded in 2015 as a university spin-off by renowned research psychologists. Headquartered in Hamburg, Germany, with an additional office in Berlin, HelloBetter offers a range of online psychological training programs aimed at managing conditions such as stress, depression, anxiety, panic disorders, and sleep disturbances. The company's innovative approach has led to the approval of six of its online therapy programs as prescription digital therapeutics under the German DiGA framework, allowing them to be accessed at no cost by over 73 million people in Germany. With a total of ten digital therapeutics evaluated in numerous randomized controlled trials, HelloBetter is committed to making evidence-based mental health care accessible worldwide. The company is actively expanding its reach beyond the DACH region, supported by a recent funding round.

Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, particularly advanced kidney cancer, also known as metastatic renal cancer. The company's primary focus is on the toxin orellanine, which is derived from specific mushroom species and has shown potential as a powerful anti-tumor agent. Oncorena aims to confirm the efficacy of orellanine in targeting and selectively destroying renal proximal tubular epithelial cells, including those that have transformed into cancerous cells and formed metastases. Through its research, Oncorena seeks to provide effective pharmacological solutions that can improve outcomes for patients battling this challenging form of cancer.

Elsa Science AB, founded in 2017 and based in Stockholm, Sweden, operates a digital health platform focused on rheumatoid arthritis. The company empowers patients to take an active role in their healthcare by providing tools that facilitate personal research into their condition. Through its application, users can monitor symptoms, diet, and lifestyle factors, gaining insights into how these elements influence their disease activity. Elsa collaborates with the Riskminder foundation and scientific studies at Karolinska Institutet to deliver reliable data and research findings. By enabling patients to track their responses to medications and overall health status, Elsa supports healthcare professionals in managing chronic diseases more effectively, improving treatment personalization and proactive care.

HelloBetter is a pioneering company in the field of digital therapeutics for mental health, founded in 2015 as a university spin-off by renowned research psychologists. Headquartered in Hamburg, Germany, with an additional office in Berlin, HelloBetter offers a range of online psychological training programs aimed at managing conditions such as stress, depression, anxiety, panic disorders, and sleep disturbances. The company's innovative approach has led to the approval of six of its online therapy programs as prescription digital therapeutics under the German DiGA framework, allowing them to be accessed at no cost by over 73 million people in Germany. With a total of ten digital therapeutics evaluated in numerous randomized controlled trials, HelloBetter is committed to making evidence-based mental health care accessible worldwide. The company is actively expanding its reach beyond the DACH region, supported by a recent funding round.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, founded in 2016. It operates a cloud-based platform designed specifically for healthcare providers to enhance and digitize patient care services. The platform utilizes advanced technology to simulate the patient interview process conducted by doctors, facilitating efficient information gathering, decision support, and documentation. By automating and simplifying various aspects of the patient journey, Doctrin aims to improve the effectiveness of healthcare professionals and contribute to better patient outcomes. The company's solutions are geared towards streamlining operations for healthcare providers, ultimately enhancing the overall healthcare system.

ADCendo ApS is a biotech company focused on the development of innovative anti-cancer therapies, specifically through the creation of antibody-drug conjugates (ADCs). These conjugates are designed to target receptors that are overexpressed in various forms of cancer, addressing significant unmet medical needs in the treatment landscape. ADCendo's approach aims to enhance targeted therapy for patients suffering from conditions such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, among others. By developing new medicines that effectively target carcinomas—including breast, colon, pancreatic, prostate, ovarian, and renal cancers—ADCendo seeks to improve treatment outcomes for cancer patients.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.

InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Priothera Ltd is a clinical-stage biotechnology company based in Dublin, Ireland, with an additional location in Saint Louis, France. Founded in 2020, Priothera specializes in the development of orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's leading candidate, mocravimod, is designed to reduce the egress of T cell subsets from lymphatic tissue, thereby enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. By providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects, Priothera aims to significantly improve outcomes for patients undergoing such transplants.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, founded in 2016. It operates a cloud-based platform designed specifically for healthcare providers to enhance and digitize patient care services. The platform utilizes advanced technology to simulate the patient interview process conducted by doctors, facilitating efficient information gathering, decision support, and documentation. By automating and simplifying various aspects of the patient journey, Doctrin aims to improve the effectiveness of healthcare professionals and contribute to better patient outcomes. The company's solutions are geared towards streamlining operations for healthcare providers, ultimately enhancing the overall healthcare system.

Spruce Biosciences, Inc. is a biopharmaceutical company based in Daly City, California, specializing in the development and commercialization of innovative therapies for rare endocrine disorders. Founded in 2014, the company is primarily focused on its lead product candidate, tildacerfont, which is undergoing clinical trials for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH). Tildacerfont is being developed as a non-steroidal therapy aimed at improving disease management and reducing reliance on steroids for affected patients. Additionally, the company is exploring the use of tildacerfont for females with polycystic ovary syndrome. With a commitment to addressing the unmet medical needs of patients with rare endocrine conditions, Spruce Biosciences aims to enhance the quality of life for those who have been historically underserved by existing treatment options. The company also has a partnership with Eli Lilly and Company to explore further pharmaceutical applications of its compounds.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, particularly advanced kidney cancer, also known as metastatic renal cancer. The company's primary focus is on the toxin orellanine, which is derived from specific mushroom species and has shown potential as a powerful anti-tumor agent. Oncorena aims to confirm the efficacy of orellanine in targeting and selectively destroying renal proximal tubular epithelial cells, including those that have transformed into cancerous cells and formed metastases. Through its research, Oncorena seeks to provide effective pharmacological solutions that can improve outcomes for patients battling this challenging form of cancer.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, founded in 2011. The company focuses on developing pharmaceutical therapies, particularly sevuparin, a novel treatment for sickle cell disease, a painful inherited blood disorder affecting millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is exploring the potential of sevuparin to address other conditions characterized by severe systemic inflammation, including sepsis, endotoxemia, severe malaria, and anemia related to chronic inflammation. The company's innovative approach aims not only to improve patient outcomes but also to reduce healthcare costs associated with these serious medical conditions. Modus Therapeutics operates as a subsidiary of Dilafor AB.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, founded in 2016. It operates a cloud-based platform designed specifically for healthcare providers to enhance and digitize patient care services. The platform utilizes advanced technology to simulate the patient interview process conducted by doctors, facilitating efficient information gathering, decision support, and documentation. By automating and simplifying various aspects of the patient journey, Doctrin aims to improve the effectiveness of healthcare professionals and contribute to better patient outcomes. The company's solutions are geared towards streamlining operations for healthcare providers, ultimately enhancing the overall healthcare system.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Tisbury Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for primary open-angle glaucoma. Established in 2017 and located in Beverly, Massachusetts, the company is advancing its clinical candidate, R-801. This innovative treatment works by enhancing fluid flow through the trabecular meshwork, utilizing mechanisms such as redox catalysis and K+-ATP channel activation. The company’s objective is to effectively reduce intraocular pressure, thereby providing significant relief for patients suffering from glaucoma.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

LTB4 is developing a naturally occurring molecule stimulating the innate immunity system to target diseases such as infections and cancer.

IDEA AG is a biopharmaceutical company based in Munich, Germany, founded in 1993. The company specializes in the development and commercialization of non-invasive, targeted therapeutics for dermatology and pain management. IDEA AG utilizes innovative drug delivery systems, such as Transfersome carriers, to facilitate the selective transport of drugs through the skin. Among its therapeutic products is Diractin, a ketoprofen-based gel designed for the treatment of peripheral pain. The company aims to enhance the efficacy of therapies for patients suffering from dermatological diseases, thereby improving treatment outcomes and patient experiences.

Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative treatments for liver disease, obesity, and vaccines. The company’s pipeline includes HepTcell, an immunotherapeutic candidate for chronic hepatitis B, which has successfully completed Phase I clinical trials. Altimmune also develops NasoShield, an intranasal anthrax vaccine, and NasoVAX, a recombinant intranasal vaccine. Additionally, the company is advancing AdCOVID, a single-dose intranasal vaccine for COVID-19. In the preclinical stage, Altimmune is working on ALT-801, a peptide-based dual GLP-1/glucagon receptor agonist for non-alcoholic steatohepatitis, as well as ALT-702, a tumor immunostimulant aimed at cancer treatment. The company employs proprietary technology for non-invasive intranasal delivery of its products and collaborates with institutions such as the University of Alabama at Birmingham to further its research initiatives.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

Glionova AB is a development stage biopharmaceutical company based in Stockholm, Sweden, established in 2014. The company specializes in creating therapies for challenging cancers, with a primary focus on glioblastoma, a common and aggressive brain tumor. Its lead product, GLN-1001, is an orally bioavailable small molecule designed to selectively induce cell death in glioblastoma cells while preserving normal brain tissue. Glionova aims to advance its product through strategic partnerships with global pharmaceutical companies specializing in oncology.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

Wilson Therapeutics, headquartered in Stockholm, Sweden, specializes in developing innovative treatments for rare diseases, primarily focusing on Wilson Disease, a condition caused by excessive copper accumulation. The company's lead product, Decuprate®, is currently undergoing Phase II clinical trials as a potential new therapy for Wilson Disease patients.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that specializes in developing therapeutics for rare and ultra-rare diseases, particularly serious genetic disorders. The company focuses on identifying and commercializing innovative treatments that address significant unmet medical needs. Its product portfolio includes Crysvita, which is used to treat X-linked hypophosphatemia, and Mepsevii, indicated for Mucopolysaccharidosis VII. By leveraging existing scientific knowledge and emphasizing clear mechanisms of action, Ultragenyx aims to create impactful therapies for conditions that currently lack effective treatments. The company prioritizes efficient development strategies in a field characterized by limited information and established precedents, drawing on the management team's expertise to advance its mission of improving patient outcomes in rare disease populations.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

SpineVision S.A. is a spinal technology company that specializes in the design, development, and marketing of implants and instrumentation for spinal treatment. Founded in 1999 and headquartered in Antony, France, the company has subsidiaries in Belgium, Italy, the United Kingdom, and the United States. SpineVision's product offerings include a range of systems addressing various spinal pathologies, such as lumbar degenerative disc diseases, deformities, cervical disorders, trauma, and tumors. Notable products include the Flex+ stabilization system, the X-PLUS spine system, and the LUMIS range for lumbar degenerative conditions. The company collaborates with leading neurological and orthopedic surgeons, resulting in over 20 patents that enhance its innovative capabilities. SpineVision aims to provide effective solutions that improve patient outcomes in spinal treatment.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that specializes in developing therapeutics for rare and ultra-rare diseases, particularly serious genetic disorders. The company focuses on identifying and commercializing innovative treatments that address significant unmet medical needs. Its product portfolio includes Crysvita, which is used to treat X-linked hypophosphatemia, and Mepsevii, indicated for Mucopolysaccharidosis VII. By leveraging existing scientific knowledge and emphasizing clear mechanisms of action, Ultragenyx aims to create impactful therapies for conditions that currently lack effective treatments. The company prioritizes efficient development strategies in a field characterized by limited information and established precedents, drawing on the management team's expertise to advance its mission of improving patient outcomes in rare disease populations.

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, the company has developed the SmartFocus technology, which utilizes navigated transcranial magnetic stimulation (TMS) with 3D navigation for precise targeting of brain areas. Nexstim's product offerings include the NBT system, designed for treating major depressive disorder and chronic neuropathic pain, and the NBS system, used for pre-surgical mapping of the speech and motor cortices. The NBS systems are primarily sold to universities and teaching hospitals. Nexstim operates in various markets, including Finland, Europe, and North America, with a significant portion of its revenue generated in North America. The company's commitment lies in addressing significant unmet clinical needs and improving the quality of life for patients.

Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Oncos Therapeutics Ltd. is a clinical-stage biotechnology company based in Helsinki, Finland, specializing in the development and commercialization of targeted cancer immunotherapy products. Founded in 2009, the company focuses on creating innovative therapies using its proprietary adenovirus-based platform. One of its main products, ONCOS-102, is an engineered human serotype 5 adenovirus designed to provoke systemic anti-tumor T cell responses in patients with various types of cancer, including soft tissue sarcoma, ovarian cancer, and mesothelioma. Oncos Therapeutics also operates an Advanced Therapy Access Program, initiated in 2007, which has provided tailored oncolytic virus therapies to around 200 patients who have not responded to standard treatments, demonstrating promising safety and efficacy results. The company's work is grounded in extensive scientific research conducted at the University of Helsinki, which underpins its ongoing clinical development efforts.

Immune Targeting Systems Limited is a biotechnology company focused on developing synthetic vaccines for mutating viruses. Based in London at the London BioScience Innovation Centre, the company was founded in late 2003. Its core technology involves targeting highly conserved parts of viruses to direct a T-cell immune response against infected cells. The company's fluoropeptide vaccine technology delivers these antigens into the body, promoting robust T-cell immunity without needing potentially toxic adjuvants typically used to boost vaccine responses. ITS is developing FP-01, a synthetic vaccine effective against various seasonal and pandemic influenza strains, as well as vaccines for life-threatening viral infections such as HIV/AIDS, hepatitis, and FIV (cat AIDS).

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

BeneChill, Inc. is a medical device company based in San Diego, California, specializing in the development of non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Founded in 2004, BeneChill's flagship product, the RhinoChill System, is designed to effectively reduce patient temperature, which is critical in improving survival rates and recovery in critical care settings. The company's innovative approach addresses a significant need in the healthcare sector by providing advanced solutions that support patient care during life-threatening situations.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of novel anti-infectives aimed at women's health. Founded in 2008, Lumavita focuses on addressing infections that affect women, with key products including FemiFect, an antibiotic designed to treat vaginitis caused by various pathogens, and SPK-601, which targets human papilloma virus (HPV) and herpes simplex virus (HSV). The company operates as a subsidiary of Shogoo Pharmaceuticals KK and distributes its products through a network of distributors. Lumavita AG was previously known as Shogoo Pharmaceuticals, AG before rebranding in 2007.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focusing on the development and commercialization of innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company specializes in orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors, aiming to inhibit the inappropriate immune responses associated with various diseases. Its lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently in Phase III development for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and in Phase IIb trials for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing several other candidates, including CCX140, an inhibitor targeting the CCR2 receptor for diabetic nephropathy and focal segmental glomerulosclerosis, and CCX872, a selective CCR2 inhibitor in Phase Ib trials for advanced pancreatic cancer. Founded in 1996, ChemoCentryx continues to drive innovation in targeted therapies for rare and complex diseases.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, the company has developed the SmartFocus technology, which utilizes navigated transcranial magnetic stimulation (TMS) with 3D navigation for precise targeting of brain areas. Nexstim's product offerings include the NBT system, designed for treating major depressive disorder and chronic neuropathic pain, and the NBS system, used for pre-surgical mapping of the speech and motor cortices. The NBS systems are primarily sold to universities and teaching hospitals. Nexstim operates in various markets, including Finland, Europe, and North America, with a significant portion of its revenue generated in North America. The company's commitment lies in addressing significant unmet clinical needs and improving the quality of life for patients.

Immune Targeting Systems Limited is a biotechnology company focused on developing synthetic vaccines for mutating viruses. Based in London at the London BioScience Innovation Centre, the company was founded in late 2003. Its core technology involves targeting highly conserved parts of viruses to direct a T-cell immune response against infected cells. The company's fluoropeptide vaccine technology delivers these antigens into the body, promoting robust T-cell immunity without needing potentially toxic adjuvants typically used to boost vaccine responses. ITS is developing FP-01, a synthetic vaccine effective against various seasonal and pandemic influenza strains, as well as vaccines for life-threatening viral infections such as HIV/AIDS, hepatitis, and FIV (cat AIDS).

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

CoreValve is a private company founded in 2001 by Dr. Jacques Seguin, a cardiac surgeon, with the aim of innovating heart valve replacement technologies. The company specializes in developing catheter-based aortic valve replacement products, allowing for the replacement of failing aortic heart valves without the need for traditional surgical access. CoreValve has successfully performed the ReValving™ procedure on over 200 patients, demonstrating the efficacy of its technology. While the current focus is on percutaneous aortic valve replacement, CoreValve plans to expand its efforts to include other minimally invasive treatments for structural heart disease. Headquartered in Irvine, California, the company is positioned in a region known for its advancements in heart valve technologies.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

CoreValve is a private company founded in 2001 by Dr. Jacques Seguin, a cardiac surgeon, with the aim of innovating heart valve replacement technologies. The company specializes in developing catheter-based aortic valve replacement products, allowing for the replacement of failing aortic heart valves without the need for traditional surgical access. CoreValve has successfully performed the ReValving™ procedure on over 200 patients, demonstrating the efficacy of its technology. While the current focus is on percutaneous aortic valve replacement, CoreValve plans to expand its efforts to include other minimally invasive treatments for structural heart disease. Headquartered in Irvine, California, the company is positioned in a region known for its advancements in heart valve technologies.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Algeta ASA is an oncology company headquartered in Oslo, Norway, that specializes in developing targeted therapies for cancer treatment using its proprietary alpha-pharmaceutical platform. Founded in 1997, the company focuses on fulfilling unmet medical needs in cancer care. Its lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing its research on thorium-227, an alpha-emitter that is in the preclinical phase and is being developed in conjunction with tumor-targeting molecules to create targeted thorium conjugates. The company has a collaboration agreement with Bayer Pharma AG for the global development and commercialization of radium-223. Algeta was previously known as Anticancer Therapeutic Inventions AS before rebranding in 2003.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland, specializing in the discovery and development of therapeutics for autoimmune and inflammatory diseases. The company’s innovative approach revolves around modifying epithelial permeability through compounds that regulate tight junctions in cellular barriers, addressing conditions related to autoimmunity. Alba's research targets a variety of disorders, including celiac disease, asthma, chronic obstructive pulmonary disease (COPD), and acute lung injury, as well as other immune-mediated and inflammatory diseases. The company's focus extends to therapeutic areas such as type 1 diabetes, inflammatory bowel disease (IBD), mucosal vaccines, and drug delivery systems, aiming to improve treatment outcomes for patients suffering from diverse health challenges.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

CoreValve is a private company founded in 2001 by Dr. Jacques Seguin, a cardiac surgeon, with the aim of innovating heart valve replacement technologies. The company specializes in developing catheter-based aortic valve replacement products, allowing for the replacement of failing aortic heart valves without the need for traditional surgical access. CoreValve has successfully performed the ReValving™ procedure on over 200 patients, demonstrating the efficacy of its technology. While the current focus is on percutaneous aortic valve replacement, CoreValve plans to expand its efforts to include other minimally invasive treatments for structural heart disease. Headquartered in Irvine, California, the company is positioned in a region known for its advancements in heart valve technologies.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of innovative protein therapeutics. Headquartered in South San Francisco, California, the company employs its proprietary ProScreen Engine to systematically screen relevant proteins in the human body, facilitating the identification of optimal treatments for various clinical indications. Five Prime's key product candidates include Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b, currently in Phase 3 clinical trials for gastric cancer, and FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for multiple cancers. Other notable candidates are FPT155, a soluble CD80 fusion protein enhancing T cell co-stimulation, and Cabiralizumab, which inhibits the colony stimulating factor-1 receptor in combination with Opdivo for cancer treatment. Additionally, Five Prime has active collaborations with several prominent pharmaceutical companies, enhancing its research and development capabilities. Founded in 2001, Five Prime Therapeutics is committed to advancing novel therapies to address challenging medical needs.

Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focusing on the development and commercialization of innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company specializes in orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors, aiming to inhibit the inappropriate immune responses associated with various diseases. Its lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently in Phase III development for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and in Phase IIb trials for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing several other candidates, including CCX140, an inhibitor targeting the CCR2 receptor for diabetic nephropathy and focal segmental glomerulosclerosis, and CCX872, a selective CCR2 inhibitor in Phase Ib trials for advanced pancreatic cancer. Founded in 1996, ChemoCentryx continues to drive innovation in targeted therapies for rare and complex diseases.